Kaplan Fox Encourages Smartsheet Inc. (NYSE: SMAR) Investors to Contact the Firm Before the Deadline on October 5, 2026

Smartsheet (NYSE: SMAR) is facing a class action lawsuit from sellers during June 1, 2024 to Sept. 23, 2024, alleging the company repurchased its shares while knowing it had received a formal acquisition offer from a Blackstone/Vista consortium at prices above then-current market levels. The complaint claims Smartsheet allegedly failed to disclose the acquisition offer or otherwise abstain from repurchasing, potentially disadvantaging investors. While no financial impact is quantified in the article, the allegations introduce reputational and litigation risk that could weigh on the stock.

Analysis

This is mostly a litigation-overhang event, not a fundamentals event. For SMAR, the economic leakage is usually bounded by settlement economics and D&O insurance, so the equity impact is more about headline volatility and a slower multiple re-rate than a meaningful hit to operating value. The real short-term risk is procedural: if discovery uncovers board/process documents that look bad, plaintiffs gain leverage and the overhang can persist for quarters, even if ultimate damages remain modest.

BX is only a second-order loser because the sponsor angle raises scrutiny around disclosure and execution in future take-privates. That can modestly increase diligence burden and slow sponsor-led deal timelines, which is a reputational/multiple issue rather than a P&L issue. BAC looks essentially unaffected unless there is hidden financing exposure, which is not apparent here.

The market may be underestimating how little this changes intrinsic value and overestimating how much it changes sentiment. The contrarian tell is that legal noise often fades quickly once there is either a motion-to-dismiss win or a reserve that looks fully insured; if that happens, any sympathy weakness in BX or software peers should reverse over 1-3 months. Falsifiers are simple: a large reserve, additional suits, or specific document evidence that the company knowingly traded against shareholders.

Key Decisions for Investors

• SMAR: no fresh directional trade into the headline; wait for the first amended complaint and any D&O reserve language. If the stock sells off >5% on no new evidence, consider a small tactical long for a 1-3 month mean reversion trade.
• BX: treat any sympathy weakness as buyable rather than a fundamental short. Add on dips of ~1% or more if there is no follow-on disclosure tying BX to financing, indemnity, or process defects.
• Software peers: if SMAR weakness spills into the group, use it as a pair trade opportunity long quality software vs short SMAR only if borrow/liquidity are workable; otherwise avoid forcing a trade.
• Alert item: if defendants disclose a material settlement reserve, insurance coverage dispute, or adverse discovery, the trade shifts from noise to real liability—then SMAR becomes a short until the docket clarifies.